英国Enigma Diagnostics  
Enigma DiagnosticsLimited是一家总部位于英国的未上市公司，致力于为分散和即时设置开发新一代快速分子诊断仪器平台。

　　Enigma的创新型专有技术将实时聚合酶链反应的速度和灵敏度与现场分散与即时测试所需的简易性相结合，可以在45分钟之内提供原始样本的测试结果。

　　该公司正瞄准众多价值数十亿英磅的市场，重点则放在临床和高值应用市场。Enigma的商业战略是最大化其市场领先的快速诊断即时与现场设备与化验平台的持续运转带来的营收，这些设备和平台来源于该公司广泛的已发布和提交专利申请的知识产权组合。Enigma将与一些市场领导者合作，这些市场领导者需要有全球的市场渗透力，并且要适当建立内部销售和营销能力以指导其产品的分销过程。

　　Enigma 拥有 Defence Science TechnologyLaboratory授予的一系列专利（这些专利体现了英国国防部 (UK Ministry ofDefence)逾15年来对研究的大力支持）的独家许可以及美国应用生物系统公司 (Applied Biosystems) 和CeleraLicences的实时聚合酶链反应设备推广的许可。Enigma的研发活动已经产生了50多个致力于实时聚合酶链反应和更广泛分子技术的全球专利系列。这些专利中有许多已经得到美国、欧盟和日本等核心商业地区的承认，并且在众多其它关键地区也有范围更广的申请和授权。

Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings. Enigma’s innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma’s commercialisation strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of- care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.